Advertisement
ABBV or BMY or NVS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Bristol-Myers Squibb (BMY) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- ABBV, BMY, and NVS represent leading pharmaceutical companies with diversified portfolios in immunology, oncology, and cardiovascular therapies.
- Recent market activity shows BMY trading near $62 with strong year-to-date gains exceeding the broader market, supported by upcoming quarterly earnings expectations.
- ABBV and NVS continue to demonstrate resilience in core therapeutic areas amid sector-wide focus on pipeline advancements and regulatory updates.
- Valuation metrics across the trio reflect sensitivity to earnings growth, patent dynamics, and global healthcare spending trends in the current environment.
- Relative performance highlights trade-offs between stability in established products and exposure to new product launches or acquisitions.
- Sector sentiment remains influenced by macroeconomic factors and company-specific catalysts rather than uniform directional moves.
Introduction
Pharmaceutical stocks such as ABBV, BMY, and NVS offer investors exposure to defensive growth characteristics within the healthcare sector. These companies operate in a mature industry shaped by innovation in drug development, regulatory approvals, and evolving payer dynamics. This comparison appeals to traders and investors seeking to evaluate relative positioning among established players with substantial market capitalizations and global operations. Analysis of recent performance, business models, and sentiment shifts can inform portfolio allocation decisions focused on risk-adjusted returns and sector diversification.
AbbVie Overview and Recent Performance
AbbVie develops and commercializes therapies primarily in immunology, oncology, and neuroscience. Its portfolio includes established products alongside newer entrants driving incremental revenue. In recent weeks, ABBV has exhibited steady trading patterns amid broader market volatility, with performance influenced by updates on product launches and competitive positioning in key therapeutic categories. Sentiment has reflected measured optimism tied to pipeline progress and operational execution, supporting relative stability compared to more cyclical sectors.
Bristol-Myers Squibb Overview and Recent Performance
Bristol-Myers Squibb focuses on oncology, hematology, immunology, and cardiovascular treatments. The company maintains a broad pipeline supported by both internal development and strategic partnerships. Recent market activity for BMY includes trading levels near $62 as of late July 2026, with year-to-date returns outperforming the S&P 500. Performance has been shaped by anticipation surrounding the July 30 earnings release, where analysts project EPS growth alongside revenue expectations near $11.67 billion. Positive sentiment stems from reaffirmed full-year guidance and product-related developments.
Novartis Overview and Recent Performance
Novartis operates across oncology, cardiovascular, neuroscience, and immunology, with additional presence in generics and biosimilars. The company emphasizes targeted therapies and global commercialization. In recent market activity, NVS has shown consistent performance supported by steady demand in core franchises and ongoing regulatory milestones. Sentiment reflects a balanced view of long-term growth drivers tempered by currency fluctuations and competitive pressures in select markets.
Trending AI Robots
Tickeron’s Trending AI Robots page curates high-performing automated trading systems from a library of hundreds of AI Trading Bots that cover thousands of different tickers. Only those demonstrating the strongest alignment with prevailing market conditions receive placement in this section. Available bots span diverse trading styles, strategies, timeframes, performance profiles, and ticker sets, with statistics often highlighting win rates, profit factors, and drawdown ranges that vary widely by configuration. This resource allows users to explore data-driven approaches suited to individual risk preferences and market outlooks. Explore the full selection on the Trending AI Robots page.
Head-to-Head Comparison
ABBV emphasizes immunology leadership with high-margin products, offering defensive characteristics but facing eventual biosimilar competition. BMY balances oncology strength with emerging cardiovascular opportunities, showing recent momentum tied to earnings visibility. NVS provides broader diversification including generics, which can moderate volatility but may compress margins relative to pure-play innovators. Growth drivers differ: pipeline depth for ABBV and BMY versus global scale and cost discipline at NVS. Risk factors include patent cliffs for all three, alongside varying exposure to U.S. pricing reforms. Valuation sensitivity appears highest for growth-oriented names during earnings seasons, while market sentiment favors those with clearer near-term catalysts.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings visibility, and relative positioning, Tickeron’s AI would currently assign a modestly higher probability of favorability to BMY in the near term. This assessment draws from its recent outperformance metrics and upcoming data points that could reinforce momentum, though outcomes remain contingent on execution and broader market conditions. Comparative stability at ABBV and diversification at NVS present viable alternatives depending on investor time horizon and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileBMY’s FA Score has 3 green FA rating(s), and NVS’s FA Score reflects 4 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- BMY’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 6 bullish TA indicator(s), and NVS’s TA Score reflects 7 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 5 bearish.
- BMY’s TA Score: 6 bullish, 3 bearish.
- NVS’s TA Score: 7 bullish, 2 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.91% price change this week, while BMY (@Pharmaceuticals: Major) price change was +2.22% , and NVS (@Pharmaceuticals: Major) price fluctuated +0.81% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.02%. For the same industry, the average monthly price growth was -1.87%, and the average quarterly price growth was +8.70%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 31, 2026.
BMY is expected to report earnings on Jul 30, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.02% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | BMY | NVS | |
| Capitalization | 458B | 127B | 295B |
| EBITDA | 16.9B | 15B | 22.4B |
| Gain YTD | 16.194 | 18.999 | 15.830 |
| P/E Ratio | 127.14 | 17.39 | 23.42 |
| Revenue | 62.8B | 48.5B | 56.6B |
| Total Cash | N/A | N/A | 6.98B |
| Total Debt | 72.9B | 46.4B | 47B |
ABBV | BMY | NVS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 94 | 33 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 4 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 83 | 6 | |
SMR RATING 1..100 | 1 | 25 | 28 | |
PRICE GROWTH RATING 1..100 | 7 | 14 | 46 | |
P/E GROWTH RATING 1..100 | 17 | 54 | 23 | |
SEASONALITY SCORE 1..100 | 28 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (4) in the Pharmaceuticals Major industry is in the same range as NVS (8) and is somewhat better than the same rating for ABBV (66). This means that BMY's stock grew similarly to NVS’s and somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is in the same range as NVS (6) and is significantly better than the same rating for BMY (83). This means that ABBV's stock grew similarly to NVS’s and significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (25) and is in the same range as NVS (28). This means that ABBV's stock grew similarly to BMY’s and similarly to NVS’s over the last 12 months.
ABBV's Price Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as BMY (14) and is somewhat better than the same rating for NVS (46). This means that ABBV's stock grew similarly to BMY’s and somewhat faster than NVS’s over the last 12 months.
ABBV's P/E Growth Rating (17) in the Pharmaceuticals Major industry is in the same range as NVS (23) and is somewhat better than the same rating for BMY (54). This means that ABBV's stock grew similarly to NVS’s and somewhat faster than BMY’s over the last 12 months.
| ABBV | BMY | NVS | |
|---|---|---|---|
| RSI ODDS (%) | 4 days ago 39% | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 46% | 4 days ago 56% | 4 days ago 59% |
| Momentum ODDS (%) | 4 days ago 64% | 4 days ago 54% | 4 days ago 52% |
| MACD ODDS (%) | 4 days ago 50% | 4 days ago 59% | 4 days ago 40% |
| TrendWeek ODDS (%) | 4 days ago 62% | 4 days ago 53% | 4 days ago 53% |
| TrendMonth ODDS (%) | 4 days ago 64% | 4 days ago 57% | 4 days ago 50% |
| Advances ODDS (%) | 4 days ago 59% | 4 days ago 54% | 11 days ago 52% |
| Declines ODDS (%) | 14 days ago 48% | 27 days ago 55% | 14 days ago 46% |
| BollingerBands ODDS (%) | 4 days ago 45% | 4 days ago 56% | 4 days ago 59% |
| Aroon ODDS (%) | 4 days ago 66% | 4 days ago 67% | 4 days ago 48% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BIASX | 22.31 | 0.12 | +0.54% |
| Brown Advisory Small-Cap Growth Inv | |||
| WFEHX | 17.06 | 0.07 | +0.41% |
| Allspring International Equity R6 | |||
| JCNCX | 26.48 | N/A | N/A |
| Janus Henderson Contrarian C | |||
| CISAX | 9.34 | N/A | N/A |
| Copeland International Small Cap A | |||
| GSPTX | 37.94 | -0.01 | -0.03% |
| Goldman Sachs Large Cap Equity Inv | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.95% | ||
| BMY - ABBV | 52% Loosely correlated | +0.94% | ||
| NVS - ABBV | 50% Loosely correlated | -0.72% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.22% | ||
| MRK - ABBV | 45% Loosely correlated | +0.45% | ||
| JNJ - ABBV | 42% Loosely correlated | +1.59% | ||
More | ||||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.